Patient outcomes in this trial were compared between the regimens of lenalidomide, bortezomib, and dexamethasone and daratumumab, lenalidomide, bortezomib, and dexamethasone for use against multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results